Korea's First Musculoskeletal DTx “MoraCure” Hits Hospitals

EverEx's musculoskeletal digital therapeutic (DTx) “MORACure” has received Korea's first grace period from the new health technology assessment requirement in this field. Hospital prescriptions began this month. Patients can now continue rehabilitation started in the hospital at home, under a doctor's prescription. The move is expected to be a turning point for the digital rehab market.

Yoon Chan, CEO of EverEx, said on the 8th that “MORACure prescriptions began on the 1st at 20 university hospitals across Korea.” He added: “No competing musculoskeletal DTx has entered clinical trials yet, so MORACure will likely dominate prescriptions for the next two years or so.”

Photo Image
EverEx's “MORACure” (Photo: EverEx)

MORACure targets patellofemoral pain (PFP), the most common form of front-of-the-knee pain. It is especially frequent among young and active people, a trend fueled partly by the running boom. The product combines personalized exercise therapy with cognitive behavioral therapy (CBT).

The app uses computer vision AI to analyze a user's movements and functional level, then builds a customized rehab exercise program. It also delivers pain-focused CBT content designed by a psychiatrist. This lets it address both physical recovery and the fear of pain at the same time. Patients use the doctor-prescribed mobile app for eight weeks.

Prescriptions are starting mainly with specialists in orthopedics, physical medicine and rehabilitation, and anesthesiology and pain medicine at the 20 university hospitals. Everex aims to expand to specialty hospitals and local clinics.

Daewoong Pharmaceutical is leading sales to prescribing institutions. It plans to use its existing sales network and marketing capabilities to bring MORACure into more clinical settings.

The partnership began last November, when Everex raised a total of KRW4 billion in strategic investment from Daewoong Investment and Naver. Daewoong now handles MORACure's domestic distribution, which should speed up adoption of musculoskeletal DTx in Korea. Daewoong plans to pair drug therapy with digital therapeutics to build an integrated musculoskeletal solution covering pain relief, rehabilitation, and refracture prevention.

Industry watchers say the first domestic musculoskeletal DTx could expand the market. It extends rehab that was once available only in hospitals into patients' daily lives. Consistency is key in rehab, but patients often struggle to reproduce the movements they learned in the clinic at home. Getting posture and exercise intensity right on their own is hard.

Yoon also said: “MORACure is backed by clinical evidence from 10 hospitals in Korea. We expect active hospital prescriptions over the next two years as a non-reimbursed (out-of-pocket) treatment.”

· This article was translated using AI and was published after final review by the reporter.